Cidara Therapeutics (CDTX) Reports Q4 Loss of $0.88/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
March 15, 2017 5:22 PM EDTSAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its corporate activities and product pipeline.
Cidara continued to make progress throughout the year in moving our development programs forward, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. We executed on our CD101 clinical programs, strengthened our finances and selected a development candidate, CD201, from our Cloudbreak immunotherapy program for the treatment of multi-drug resistant... More
